Literature DB >> 10952606

Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.

D F Sahm1, D E Peterson, I A Critchley, C Thornsberry.   

Abstract

As the most commonly used fluoroquinolone in the United States since 1987, ciprofloxacin has exerted the greatest selective pressure on S. pneumoniae and provides a valuable marker to evaluate the actual and potential emergence of fluoroquinolone resistance in this species. Analysis of susceptibility results obtained with 5,640 strains collected from throughout the United States showed that only 16 (0.3%) of the isolates demonstrated MICs of > or =4 microg/ml. The prevalence of this phenotype was significantly higher (P < 0.05) among penicillin-resistant populations, among isolates from patients >64 years old, and among respiratory isolates. However, >99% of strains had MICs of <4 microg/ml regardless of the risk group examined, and the MIC population distributions were the same for each risk group. These findings demonstrate that the phenotype of a MIC of > or =4 microg/ml remains uncommon after 10 years of ciprofloxacin use; however, these findings are no reason to become complacent with regard to appropriate use of fluoroquinolones and the need to carefully track resistance trends. Equally important is careful analysis of data that result from surveillance in terms of risk factors and other associated trends so that resistance and susceptibility, and their consequences, are neither over- nor underestimated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952606      PMCID: PMC90096          DOI: 10.1128/AAC.44.9.2521-2524.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.

Authors:  G Arcieri; E Griffith; G Gruenwaldt; A Heyd; B O'Brien; P Screen; N Becker; R August
Journal:  J Clin Pharmacol       Date:  1988-02       Impact factor: 3.126

2.  Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects.

Authors:  E A Piercy; R E Bawdon; P A Mackowiak
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; K C Kugler; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

5.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

6.  Gyrase inhibitor ciprofloxacin in human parotid saliva.

Authors:  D Adler; H Maier
Journal:  J Clin Chem Clin Biochem       Date:  1989-04

7.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

Authors:  D K Chen; A McGeer; J C de Azavedo; D E Low
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

8.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Authors:  C Janoir; V Zeller; M D Kitzis; N J Moreau; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

9.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

10.  Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study.

Authors:  C Thornsberry; P T Ogilvie; H P Holley; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

View more
  19 in total

1.  Levofloxacin-resistant Streptococcus pneumoniae: second look.

Authors:  C Thornsberry; J A Karlowsky; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America.

Authors:  J A Karlowsky; L Nealy; D F Sahm; C Thornsberry; M E Jones
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

3.  Longitudinal assessment of antipneumococcal susceptibility in the United States.

Authors:  Mark E Jones; James A Karlowsky; Renée Blosser-Middleton; Ian A Critchley; Elena Karginova; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  Biographical Feature: Clyde Thornsberry, Ph.D.

Authors:  Erik Munson
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

5.  High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.

Authors:  Ewa Sadowy; Radosław Izdebski; Anna Skoczyńska; Marek Gniadkowski; Waleria Hryniewicz
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

6.  Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.

Authors:  Ricardo Dias; Deolinda Louro; Manuela Caniça
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.

Authors:  Jeff Powis; Allison McGeer; Karen Green; Otto Vanderkooi; Karl Weiss; George Zhanel; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Ross Davidson; Kevin Forward; Daryl Hoban; Andrew Simor; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 8.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.

Authors:  James A Karlowsky; Clyde Thornsberry; Ian A Critchley; Mark E Jones; Alan T Evangelista; Gary J Noel; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Drug-resistant Streptococcus pneumoniae in Community-acquired Pneumonia.

Authors:  Michael Henry; Howard L. Leaf
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.